REVIVA PHARMACEUTICALS HOLDI (RVPH) Fundamental Analysis & Valuation

NASDAQ:RVPHUS76152G1004

Current stock price

2.32 USD
-0.25 (-9.73%)
At close:
2.3685 USD
+0.05 (+2.09%)
After Hours:

This RVPH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. RVPH Profitability Analysis

1.1 Basic Checks

  • In the past year RVPH has reported negative net income.
  • RVPH had a negative operating cash flow in the past year.
  • RVPH had negative earnings in 4 of the past 5 years.
  • RVPH had a negative operating cash flow in each of the past 5 years.
RVPH Yearly Net Income VS EBIT VS OCF VS FCFRVPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

  • RVPH has a Return On Assets of -158.77%. This is amonst the worse of the industry: RVPH underperforms 84.38% of its industry peers.
  • Looking at the Return On Equity, with a value of -500.18%, RVPH is doing worse than 80.21% of the companies in the same industry.
Industry RankSector Rank
ROA -158.77%
ROE -500.18%
ROIC N/A
ROA(3y)-169.33%
ROA(5y)-106.82%
ROE(3y)-1567.74%
ROE(5y)-946.37%
ROIC(3y)N/A
ROIC(5y)N/A
RVPH Yearly ROA, ROE, ROICRVPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

  • RVPH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RVPH Yearly Profit, Operating, Gross MarginsRVPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

4

2. RVPH Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for RVPH has been increased compared to 1 year ago.
  • Compared to 5 years ago, RVPH has more shares outstanding
  • The debt/assets ratio for RVPH is higher compared to a year ago.
RVPH Yearly Shares OutstandingRVPH Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RVPH Yearly Total Debt VS Total AssetsRVPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -4.20, we must say that RVPH is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -4.20, RVPH perfoms like the industry average, outperforming 40.10% of the companies in the same industry.
  • There is no outstanding debt for RVPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.2
ROIC/WACCN/A
WACCN/A
RVPH Yearly LT Debt VS Equity VS FCFRVPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 1.39 indicates that RVPH should not have too much problems paying its short term obligations.
  • RVPH has a Current ratio of 1.39. This is in the lower half of the industry: RVPH underperforms 72.92% of its industry peers.
  • RVPH has a Quick Ratio of 1.39. This is a normal value and indicates that RVPH is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.39, RVPH is doing worse than 65.63% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.39
Quick Ratio 1.39
RVPH Yearly Current Assets VS Current LiabilitesRVPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M

1

3. RVPH Growth Analysis

3.1 Past

  • The earnings per share for RVPH have decreased strongly by -249.55% in the last year.
EPS 1Y (TTM)-249.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-380%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, RVPH will show a very strong growth in Earnings Per Share. The EPS will grow by 21.62% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y58.3%
EPS Next 2Y32.56%
EPS Next 3Y18.76%
EPS Next 5Y21.62%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RVPH Yearly Revenue VS EstimatesRVPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 500M 1B
RVPH Yearly EPS VS EstimatesRVPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 2

0

4. RVPH Valuation Analysis

4.1 Price/Earnings Ratio

  • RVPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RVPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RVPH Price Earnings VS Forward Price EarningsRVPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RVPH Per share dataRVPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

  • RVPH's earnings are expected to grow with 18.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.56%
EPS Next 3Y18.76%

0

5. RVPH Dividend Analysis

5.1 Amount

  • No dividends for RVPH!.
Industry RankSector Rank
Dividend Yield 0%

RVPH Fundamentals: All Metrics, Ratios and Statistics

REVIVA PHARMACEUTICALS HOLDI

NASDAQ:RVPH (3/17/2026, 8:00:02 PM)

After market: 2.3685 +0.05 (+2.09%)

2.32

-0.25 (-9.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13
Earnings (Next)03-23
Inst Owners9.74%
Inst Owner Change-98.31%
Ins Owners3.01%
Ins Owner Change0%
Market Cap271.09M
Revenue(TTM)N/A
Net Income(TTM)-22.76M
Analysts81.67
Price TargetN/A
Short Float %N/A
Short Ratio6.14
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)16.25%
Min EPS beat(2)-6.95%
Max EPS beat(2)39.44%
EPS beat(4)3
Avg EPS beat(4)23.56%
Min EPS beat(4)-6.95%
Max EPS beat(4)39.44%
EPS beat(8)7
Avg EPS beat(8)18.04%
EPS beat(12)8
Avg EPS beat(12)-2.4%
EPS beat(16)11
Avg EPS beat(16)0.13%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.69%
PT rev (3m)-6.83%
EPS NQ rev (1m)-1900%
EPS NQ rev (3m)-1481.92%
EPS NY rev (1m)5.42%
EPS NY rev (3m)7.66%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 59.58
P/tB 59.58
EV/EBITDA N/A
EPS(TTM)-3.88
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS0
BVpS0.04
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -158.77%
ROE -500.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-169.33%
ROA(5y)-106.82%
ROE(3y)-1567.74%
ROE(5y)-946.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.39
Quick Ratio 1.39
Altman-Z -4.2
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-249.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-380%
EPS Next Y58.3%
EPS Next 2Y32.56%
EPS Next 3Y18.76%
EPS Next 5Y21.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y33.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.57%
OCF growth 3YN/A
OCF growth 5YN/A

REVIVA PHARMACEUTICALS HOLDI / RVPH Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for REVIVA PHARMACEUTICALS HOLDI?

ChartMill assigns a fundamental rating of 1 / 10 to RVPH.


What is the valuation status of REVIVA PHARMACEUTICALS HOLDI (RVPH) stock?

ChartMill assigns a valuation rating of 0 / 10 to REVIVA PHARMACEUTICALS HOLDI (RVPH). This can be considered as Overvalued.


What is the profitability of RVPH stock?

REVIVA PHARMACEUTICALS HOLDI (RVPH) has a profitability rating of 0 / 10.